TIME: 8:30 a.m.
EVENT: Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 45596) holds a meeting of the Antimicrobial Drugs Advisory Committee to discuss new drug application 209367, ciprofloxacin inhalation powder, sponsored by Bayer HealthCare Pharmaceuticals, Inc., for the proposed indication of reduction of exacerbations in non-cystic fibrosis bronchiectasis adult patients with respiratory bacterial pathogens.
DATE: November 16, 2017
LOCATION: FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Conference Center, the Great Room, Room 1503, Silver Spring, Md.
CONTACT: Lauren Tesh, 301-796-9001, AMDAC@fda.hhs.gov
Copyright (c) 2017 Federal Information & News Dispatch, Inc., source Washington Daybook